Literature DB >> 35679526

Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma.

Martin H Voss1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35679526      PMCID: PMC9426791          DOI: 10.1200/JCO.22.00834

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  19 in total

1.  Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.

Authors:  Anita Gul; Tyler F Stewart; Charlene M Mantia; Neil J Shah; Emily Stern Gatof; Ying Long; Kimberly D Allman; Moshe C Ornstein; Hans J Hammers; David F McDermott; Michael B Atkins; Michael Hurwitz; Brian I Rini
Journal:  J Clin Oncol       Date:  2020-06-03       Impact factor: 44.544

2.  Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply.

Authors:  Robert Motzer; Toni K Choueiri
Journal:  N Engl J Med       Date:  2021-07-15       Impact factor: 91.245

3.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

4.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

Review 5.  First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?

Authors:  Jacob J Adashek; Joshua J Breunig; Edwin Posadas; Neil A Bhowmick; Leigh Ellis; Stephen J Freedland; Hyung Kim; Robert Figlin; Jun Gong
Journal:  Drugs       Date:  2022-02-17       Impact factor: 9.546

6.  Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).

Authors:  Michael A Postow; Debra A Goldman; Alexander N Shoushtari; Allison Betof Warner; Margaret K Callahan; Parisa Momtaz; James W Smithy; Ellesa Naito; Marina K Cugliari; Vladislav Raber; Omar Eton; Suresh G Nair; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal:  J Clin Oncol       Date:  2021-12-20       Impact factor: 44.544

7.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

8.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Thomas Powles; Mauricio Burotto; Bernard Escudier; Maria T Bourlon; Bogdan Zurawski; Victor M Oyervides Juárez; James J Hsieh; Umberto Basso; Amishi Y Shah; Cristina Suárez; Alketa Hamzaj; Jeffrey C Goh; Carlos Barrios; Martin Richardet; Camillo Porta; Rubén Kowalyszyn; Juan P Feregrino; Jakub Żołnierek; David Pook; Elizabeth R Kessler; Yoshihiko Tomita; Ryuichi Mizuno; Jens Bedke; Joshua Zhang; Matthew A Maurer; Burcin Simsek; Flavia Ejzykowicz; Gisela M Schwab; Andrea B Apolo; Robert J Motzer
Journal:  N Engl J Med       Date:  2021-03-04       Impact factor: 91.245

9.  Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.

Authors:  David F McDermott; Jae-Lyun Lee; Georg A Bjarnason; James M G Larkin; Rustem A Gafanov; Mark D Kochenderfer; Niels Viggo Jensen; Frede Donskov; Jahangeer Malik; Alexandr Poprach; Scott S Tykodi; Teresa Alonso-Gordoa; Daniel C Cho; Poul F Geertsen; Miguel Angel Climent Duran; Christopher DiSimone; Rachel Kloss Silverman; Rodolfo F Perini; Charles Schloss; Michael B Atkins
Journal:  J Clin Oncol       Date:  2021-02-02       Impact factor: 44.544

10.  Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).

Authors:  Rana R McKay; Bradley A McGregor; Wanling Xie; David A Braun; Xiao Wei; Christos E Kyriakopoulos; Yousef Zakharia; Benjamin L Maughan; Tracy L Rose; Walter M Stadler; David F McDermott; Lauren C Harshman; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2020-10-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.